The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.
B7h4 antikoerper, B7s1 antikoerper, B7x antikoerper, BC032925 antikoerper, B7-H4 antikoerper, B7H4 antikoerper, B7S1 antikoerper, B7X antikoerper, B7h.5 antikoerper, PRO1291 antikoerper, VCTN1 antikoerper, RGD1311204 antikoerper, V set domain containing T cell activation inhibitor 1 L homeolog antikoerper, V-set domain containing T cell activation inhibitor 1 antikoerper, V-set domain containing T-cell activation inhibitor 1 antikoerper, V set domain containing T cell activation inhibitor 1 antikoerper, vtcn1.L antikoerper, VTCN1 antikoerper, vtcn1 antikoerper, Vtcn1 antikoerper
Hintergrund
B7-H4, also known as VTCN1, is a type I transmembrane protein and member of the B7 family. Its extracellular region consists of one IgV-like and one IgC-like domain. B7-H4 expression has been reported on activated T cells, B cells, monocytes, and dendritic cells. On T cells, B7-H4 inhibits proliferation, cytokine secretion, and cytotoxicity. B7-H4 is also expressed by different carcinomas including renal, gastric, breast, ovarian and melanoma. Its expression is associated with a poor prognosis.